Semaglutide monotherapy also significantly improved fasting glucose (Fig
1372-C NON-LINEAR ASSOCIATION OF BASELINE VIRAL LOAD WITH ON-TREATMENT HEPATOCELLULAR CARCINOMA RISK IN CHRONIC HEPATITIS B Won-Mook Choi 1 , Gi-Ae Kim 2 , Jonggi Choi 3 , Gwang Hyeon Choi 4 , Yun Bin Lee 5 , Dong Hyun Sinn 6 and Young-Suk Lim 1 , (1)Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), (2)Kyung Hee University School of Medicine, (3)Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, (4)Seoul National University Bundang Hospital, Seoul National University College of Medicine, (5)Seoul National University College of Medicine, (6)Samsung Medical Center Background: The association between baseline pre-treatment serum hepatitis B virus (HBV) DNA levels and on-treatment hepatocellular carcinoma (HCC) risk remains controversial in chronic hepatitis B (CHB) patients
Presented for research literature review only Hung CF et al
GLP-1 Plus is a compounded medication with Semaglutide and B Vitamins, used primarily to treat type 2 diabetes and obesity
clinicaltrials.gov Disclaimer: This article is for educational and research purposes only